MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB)
Drug resistant TB – latest developments in epidemiology, diagnostics and management - ScienceDirect
Building a treatment regimen for MDR-TB. | Download Scientific Diagram
Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia | PLOS ONE
Drugs and doses used in shorter MDR regimen for patients older than 14... | Download Scientific Diagram
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in ...
Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. | Semantic Scholar
Short-course BDQ-containing regimens. BDQ, bedaquiline; PO, oral... | Download Scientific Diagram
2.4 Drug-resistant TB treatment
Annex. Summary of changes in policy on DS-TB treatment since 2010 and mapping of recommendations in consolidated DS-TB guidelines | TB Knowledge Sharing
Fig. 4.1, Criteria to decide when the shorter MDR-TB regimen may be offered - WHO consolidated guidelines on drug-resistant tuberculosis treatment - NCBI Bookshelf
Molecular TB
Anti-tuberculosis treatment strategies and drug development: challenges and priorities | Nature Reviews Microbiology
Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial | BMC Infectious Diseases | Full Text
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling | Antimicrobial Agents and Chemotherapy
Frontiers | Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country
4.3 Algorithm 3 – DST for second-line drugs for RR-TB or MDR-TB patients | TB Knowledge Sharing
Timeline of changes to trial design and release of WHO treatment guidelines | Download Scientific Diagram
The global impact of household contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study - The Lancet Global Health
Drug-resistant tuberculosis: what is the situation, what are the needs to roll it back | AMR Control
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis | NEJM
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings | European Respiratory Society
WHO's Rapid Communication on Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis | Stop TB Partnership
Frontiers | Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country
WHO consolidated guidelines on drug-resistant tuberculosis treatment - NCBI Bookshelf
6.2.2 Medicines used in longer MDR-TB treatment regimens | TB Knowledge Sharing
